Navigation

Cystic fibrosis - mannitol [ID85]

Mannitol dry powder for inhalation for the treatment of cystic fibrosis

Status: History
Expected date of issue: November 2012
Referral date: July 2009
Process: STA
Topic area:
  • Digestive system
  • Respiratory
 

NICE project team

Executive Lead: Gillian Leng
Technical Lead: Pall Jonsson
Communications manager: Katie Williamson
Project manager: Jeremy Powell
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 11 February 2011
1st appraisal committee meeting: 03 April 2012
2nd appraisal committee meeting 04 September 2012
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Pharmaxis (mannitol dry powder for inhalation)

Patient/carer groups

  • Cystic Fibrosis Trust

Professional groups

  • Association of Respiratory Nurse Specialists
  • British Thoracic Society
  • Royal College of Nursing
  • Royal College of Paediatrics & Child Health
  • Royal College of Physicians
  • United Kingdom Clinical Pharmacy Association

Others

  • Department of Health
  • Sandwell PCT
  • Welsh Assembly Government

General

  • British National Formulary
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • NHS Quality Improvement Scotland

Possible comparator manufacturer(s)

  • Roche Products (Dornase Alfa)

Relevant research groups

  • None

Evidence Review Group

  • National Institute for Health ResearchHealth Technology Assessment Programme

Associated guideline group

  • None

Associated public health groups

  • None

Top


 

Project history

Date

 

Update

 

30 June 2011

 

Following an update on the regulatory status of the technology which has received a negative CHMP opinion, the 26 July 2011 committee meeting discussion for this appraisal has been cancelled. We are monitoring this situation and will provide an update as soon as possible.

23 February 2011

 

Following on from further advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore the committee meeting dates have been rescheduled.

1st Appraisal Committee meeting: 26 July 2011

2nd Appraisal Committee meeting (if required): 26 October 2011

25 October 2010

 

The manufacturer of this technology advised us that the regulatory timelines for this technology had changed. Therefore, the timelines for this appraisal have changed and it has now been rescheduled in the Technology Appraisal work programme. The committee meeting dates and expected date of issue have been updated on this web page.

 

7 October 2010

 

Please note that the manufacturer has advised us that the regulatory timelines for this technology have changed. Consequently, this will affect the timelines for the appraisal and we are currently working on rescheduling this within the Technology Appraisal work programme.

The deadline for evidence submission, which was 11 October 2010, no longer applies in this instance.

Top


 

Key documents

This page was last updated: 27 June 2013

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.